Develops small-molecule protein degrader therapeutics that selectively target and eliminate disease-causing proteins, preserving normal protein functions. This approach addresses neurodegenerative diseases such as Alzheimer’s, Huntington’s, and Parkinson’s by providing a novel, disease-modifying treatment strategy.
Funding
Funding not disclosed
Founders
Product
Problem
Many neurodegenerative diseases, such as Alzheimer’s, Huntington’s, and Parkinson’s, are characterized by the accumulation of specific disease-causing proteins. Traditional therapeutic approaches often fail to selectively target and eliminate these proteins without disrupting normal protein functions. This lack of specificity can lead to significant side effects and limited efficacy.
Solution
Origami Therapeutics is developing a new class of small-molecule therapeutics designed to selectively degrade and remove disease-related proteins, offering a potential disease-modifying approach for neurodegenerative conditions. Their ORICISION™ drug discovery platform identifies molecules that trigger the targeted elimination of specific proteins implicated in disease pathology, while preserving normal protein function. By selectively removing these harmful proteins, Origami's approach aims to address the underlying causes of neurodegenerative diseases, potentially slowing or reversing disease progression. The use of small molecules allows for broad distribution throughout the body and facilitates ease of manufacturing, potentially leading to more accessible and scalable treatments. This targeted protein degradation strategy offers a novel approach to treating diseases with limited therapeutic options.
Target Audience
The primary target audience includes patients suffering from neurodegenerative diseases, as well as pharmaceutical companies and researchers seeking novel therapeutic approaches for these conditions.
Features
- ORICISION™ Drug Discovery Platform for identifying selective protein degraders
- Small-molecule therapeutics for broad distribution and ease of manufacturing
- Targeted protein degradation to selectively remove disease-causing proteins
- Preservation of normal protein function to minimize off-target effects
- Focus on neurodegenerative diseases including Alzheimer’s, Huntington’s, Parkinson’s, ALS, and Frontotemporal Dementia